Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL512928 | 0.77 | NOTUM (0.42) | LMNAPKMRAB9ANPC1KDM4E | |
| SCHEMBL3608419 | 0.77 | GAA (0.41) | LMNAPKMMAOBRAB9ANPC1 | |
| SCHEMBL5324357 | 0.77 | ESR1 (0.43) | LMNAPKMMAOBRAB9ANPC1 | |
| SCHEMBL314750 | 0.77 | EGFR (0.47) | LMNATDP1MAOBRAB9ANPC1 | |
| SCHEMBL769225 | 0.74 | — | — | |
| SCHEMBL512281 | 0.74 | PTGS2 (0.43) | — | |
| SCHEMBL5327871 | 0.72 | KIF11 (0.43) | MAOBALDH1A1CYP1A2CYP2C19NOTUM | |
| SCHEMBL15515389 | 0.71 | — | — | |
| SCHEMBL5535370 | 0.68 | AHR (0.50) | PKMTDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4343079 | 0.67 | NQO2 (0.53) | LMNAPKMACHETDP1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421852-B9 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | claimed |
| US-8815839-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-26 | — | — | US | claimed |
| EP-2421852-B1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | claimed |
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-07-18 | — | — | US | claimed |
| US-8415341-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-04-09 | — | — | US | claimed |
| EP-2421852-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20100324015-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| WO-2010124121-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-20060052365-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-09 | — | — | US | claimed |
| JP-2006505526-A | — | — | 2006-02-16 | — | — | JP | claimed |
| EP-1539178-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004017911-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-04 | — | — | WO | claimed |
| EP-1257265-B1 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | BIOAGENCY AG (DE) | 2004-01-21 | — | — | EP | claimed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | claimed |
| EP-1257265-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | Jomaa Pharmaka GmbH (DE) | 2002-11-20 | — | — | EP | claimed |
| WO-2001070026-A2 | 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES | JOMAA PHARMAKA GMBH (DE) | 2001-09-27 | — | — | WO | claimed |
| WO-2001062709-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | JOMAA PHARMAKA GMBH (DE) | 2001-08-30 | — | — | WO | claimed |
| US-6083945-A | USEFUL IN TREATING HUMANS OR OTHER MAMMALS WITH CARDIAC ARRHYTHMIA AND/OR CARDIAC FIBRILLATION | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-04 | — | — | US | claimed |
| US-5691369-A | CARDIOVASCULAR DISORDERS | THE PROCTOR & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| CN-115315451-B | Catalyst for olefin polymerization, method for producing catalyst for olefin polymerization, and method for producing olefin polymer using catalyst for olefin polymerization | 日本聚丙烯株式会社 | 2023-12-01 | — | — | CN | disclosed |
| US-20230331881-A1 | PRODUCTION OF POLYPROPYLENE WITH LOW VOLATILES | BOREALIS AG (AT) | 2023-10-19 | — | — | US | disclosed |
| CN-114616280-B | Heterophasic propylene ethylene copolymer compositions with desirable balance of mechanical properties | 北欧化工公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230142911-A1 | OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION CATALYST PRODUCTION METHOD, AND OLEFIN POLYMER PRODUCTION METHOD USING THE OLEFIN POLYMERIZATION CATALYST | JAPAN POLYPROPYLENE CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| CN-115702174-A | Production of polypropylene with low volatiles | 博里利斯股份公司 | 2023-02-14 | — | — | CN | disclosed |
| EP-4105246-A1 | CATALYST FOR OLEFIN POLYMERIZATION, PRODUCTION METHOD FOR CATALYST FOR OLEFIN POLYMERIZATION, AND PRODUCTION METHOD FOR OLEFIN POLYMER USING SAID CATALYST FOR OLEFIN POLYMERIZATION | Japan Polypropylene Corporation (JP) | 2022-12-21 | — | — | EP | disclosed |
| US-20220396695-A1 | HETEROPHASIC PROPYLENE ETHYLENE COPOLYMER COMPOSITION WITH DESIRABLE BALANCE OF MECHANICAL PROPERTIES | BOREALIS AG (AT) | 2022-12-15 | — | — | US | disclosed |
| CN-115315451-A | Olefin polymerization catalyst, method for producing olefin polymerization catalyst, and method for producing olefin polymer using olefin polymerization catalyst | 日本聚丙烯株式会社 | 2022-11-08 | — | — | CN | disclosed |
| CN-114616280-A | Heterophasic propylene ethylene copolymer compositions having a desirable balance of mechanical properties | 北欧化工公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021254938-A1 | PRODUCTION OF POLYPROPYLENE WITH LOW VOLATILES | BOREALIS AG (AT) | 2021-12-23 | — | — | WO | disclosed |
| EP-3925986-A1 | PRODUCTION OF POLYPROPYLENE WITH LOW VOLATILES | Borealis AG (AT) | 2021-12-22 | — | — | EP | disclosed |
| CN-110483670-B | Metallocene complex and process for producing olefin polymer | 日本聚丙烯株式会社 | 2021-11-30 | — | — | CN | disclosed |
| WO-2021078857-A1 | HETEROPHASIC POLYPROPYLENE COMPOSITION WITH IMPROVED STIFFNESS AND IMPACT BEHAVIOUR | BOREALIS AG (AT) | 2021-04-29 | — | — | WO | disclosed |
| EP-3750927-A1 | HETEROPHASIC PROPYLENE COPOLYMER WITH IMPROVED MECHANICAL PROPERTIES | Borealis AG (AT) | 2020-12-16 | — | — | EP | disclosed |
| CN-110483670-A | The method of metallocene complex and production olefin polymer | JAPAN POLYPROPYLENE CORP | 2019-11-22 | — | — | CN | disclosed |
| CN-106132975-B | Metallocene complex and process for producing olefin polymer | 日本聚丙烯株式会社 | 2019-11-08 | — | — | CN | disclosed |
| EP-3121187-B1 | METALLOCENE COMPLEX AND METHOD FOR MANUFACTURING OLEFIN POLYMER | JAPAN POLYPROPYLENE CORP (JP) | 2018-10-10 | — | — | EP | disclosed |
| US-9963522-B2 | Metallocene complex and method for producing olefin polymer | JAPAN POLYPROPYLENE CORPORATION (JP) | 2018-05-08 | — | — | US | disclosed |
| US-9902749-B2 | Metallocene complex and olefin polymerization method | JAPAN POLYPROPYLENE CORPORATION (JP) | 2018-02-27 | — | — | US | disclosed |
| US-20170081431-A1 | METALLOCENE COMPLEX AND METHOD FOR PRODUCING OLEFIN POLYMER | JAPAN POLYPROPYLENE CORPORATION (JP) | 2017-03-23 | — | — | US | disclosed |
| EP-3121187-A1 | METALLOCENE COMPLEX AND METHOD FOR MANUFACTURING OLEFIN POLYMER | Japan Polypropylene Corporation (JP) | 2017-01-25 | — | — | EP | disclosed |
| CN-106132975-A | metallocene complex and process for producing olefin polymer | 日本聚丙烯株式会社 | 2016-11-16 | — | — | CN | disclosed |
| EP-2915816-B1 | METALLOCENE COMPLEX AND OLEFIN POLYMERIZATION METHOD | JAPAN POLYPROPYLENE CORP (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-20150266914-A1 | METALLOCENE COMPLEX AND OLEFIN POLYMERIZATION METHOD | JAPAN POLYPROPYLENE CORPORATION (JP) | 2015-09-24 | — | — | US | disclosed |
| EP-2915816-A1 | METALLOCENE COMPLEX AND OLEFIN POLYMERIZATION METHOD | Japan Polypropylene Corporation (JP) | 2015-09-09 | — | — | EP | disclosed |
| CN-104781270-A | Metallocene complexes and olefin polymerization process | JAPAN POLYPROPYLENE CORP | 2015-07-15 | — | — | CN | disclosed |
| EP-2421852-B9 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | disclosed |
| US-8815839-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-26 | — | — | US | disclosed |
| EP-2360163-B1 | METALLOCENE COMPLEX AND METHOD FOR POLYMERIZING OLEFIN | JAPAN POLYPROPYLENE CORP (JP) | 2014-06-25 | — | — | EP | disclosed |
| EP-2421852-B1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | disclosed |
| US-8586770-B2 | Unsaturated steroid compounds | Harbor Therapeutics, Inc. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-07-18 | — | — | US | disclosed |
| US-8461365-B2 | Metallocene complex and polymerization method of olefin | JAPAN POLYPROPYLENE CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8415341-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-04-09 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2421852-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | disclosed |
| US-20120029260-A1 | Screening and Treatment Method | BIOVIE INC. | 2012-02-02 | — | — | US | disclosed |
| CN-102245620-A | Metallocene complex and method for polymerizing olefin | JAPAN POLYPROPYLENE CORP | 2011-11-16 | — | — | CN | disclosed |
| US-20110230622-A1 | METALLOCENE COMPLEX AND POLYMERIZATION METHOD OF OLEFIN | JAPAN POLYPROPYLENE CORPORATION (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2360163-A1 | METALLOCENE COMPLEX AND METHOD FOR POLYMERIZING OLEFIN | Japan Polypropylene Corporation (JP) | 2011-08-24 | — | — | EP | disclosed |
| US-20110137057-A1 | Unsaturated Steroid Compounds | BIOVIE INC. | 2011-06-09 | — | — | US | disclosed |
| US-20110085984-A1 | Drug Product and Process for Making | BIOVIE INC. | 2011-04-14 | — | — | US | disclosed |
| US-7910755-B2 | Stem cell expansion and uses | HARBOR BIOSCIENCES, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100324015-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| WO-2010124121-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2007144379-A1 | BICYCLIC COMPOUNDS USEFUL AS CATHEPSIN S INBHIBITORS | MEDIVIR AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1807118-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070077203-A1 | Surrogate markers | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070077201-A1 | Stem cell expansion and uses | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| WO-2007030124-A2 | TREATMENT SCREENING METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070053832-A1 | Drug product and process for making | BIOVIE INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | BIOVIE INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2006110172-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS.INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006064286-A1 | CATHEPSIN S INHIBITORS | MEDIVIR UK LTD (GB) | 2006-06-22 | — | — | WO | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060088473-A1 | Treatment screening methods | BIOVIE INC. | 2006-04-27 | — | — | US | disclosed |
| US-20060073099-A1 | Treatment screening methods | BIOVIE INC. | 2006-04-06 | — | — | US | disclosed |
| US-20060052365-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-09 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1539178-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004017911-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-1257265-B1 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | BIOAGENCY AG (DE) | 2004-01-21 | — | — | EP | disclosed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | disclosed |
| EP-1257265-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | Jomaa Pharmaka GmbH (DE) | 2002-11-20 | — | — | EP | disclosed |
| EP-1231208-A2 | 4-oxocyclic ureas useful as antiarrhythmic and antifibrillatory agents | PROCTER & GAMBLE PHARMACEUTICALS (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-0598061-B1 | NOVEL 4-OXOCYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMA (US) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001070026-A2 | 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES | JOMAA PHARMAKA GMBH (DE) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001062709-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | JOMAA PHARMAKA GMBH (DE) | 2001-08-30 | — | — | WO | disclosed |
| US-6083945-A | USEFUL IN TREATING HUMANS OR OTHER MAMMALS WITH CARDIAC ARRHYTHMIA AND/OR CARDIAC FIBRILLATION | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-5994354-A | Cyclic urethanes useful as antiarrhythmic and antifibrillatory agents | THE PROCTER & GAMBLE COMPANY (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0957103-A1 | Oxazolidinone derivatives useful as antiarrhythmic and antifibrillatory agents | Procter & Gamble Pharmaceuticals, Inc. (US) | 1999-11-17 | — | — | EP | disclosed |
| EP-0891976-A1 | Novel cyclic ureas useful as antiarrhythmic and antifibrillatory agents | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5691369-A | CARDIOVASCULAR DISORDERS | THE PROCTOR & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| US-5616579-A | ADMINISTERING TO MAMMALS TO PREVENT GASTRIC ULCER | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| EP-0562833-B1 | Anti-ulcer pyridyloxy derivatives, their preparation and uses | SANKYO CO (JP) | 1996-05-08 | — | — | EP | disclosed |
| US-5462940-A | 4-oxocyclic ureas useful as antiarrhythmic and antifibrillatory agents | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0599968-A1 | CYCLIC URETHANES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1994-06-08 | — | — | EP | disclosed |
| EP-0598046-A1 | NOVEL CYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1994-05-25 | — | — | EP | disclosed |
| EP-0598061-A1 | NOVEL 4-OXOCYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1994-05-25 | — | — | EP | disclosed |
| CN-1081437-A | Antiulcer pyridine oxygen derivative, their preparation method and purposes | SANKYO CO (JP) | 1994-02-02 | — | — | CN | disclosed |
| EP-0562833-A1 | Anti-ulcer pyridyloxy derivatives, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
| WO-1993004060-A1 | NOVEL CYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004060-A1 | NOVEL CYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004064-A1 | CYCLIC URETHANES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004061-A1 | NOVEL 4-OXOCYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324015-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPC | LMNA 1955/4885PKM 2115/4885ACHE 51/4885 |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | HRH2, ASPH, NQO2 | LMNA 3574/4885PKM 3542/4885ACHE 835/4885 |
| US-20060088473-A1 | Treatment screening methods | HSD3B1, HSD3B2, HSD17B11 | LMNA 991/4885PKM 4129/4885ACHE 2420/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | LMNA 4152/4885PKM 4291/4885ACHE 4670/4885 |
| US-20070077203-A1 | Surrogate markers | TSG101, RAD50, DNASE1L3 | LMNA 230/4885PKM 4788/4885ACHE 4351/4885 |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | CYP17A1, HSD17B11, HSD3B1 | LMNA 2328/4885PKM 4073/4885ACHE 4859/4885 |
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPC | LMNA 1955/4885PKM 2115/4885ACHE 51/4885 |
| US-20110230622-A1 | METALLOCENE COMPLEX AND POLYMERIZATION METHOD OF OLEFIN | ALOX12, ALOX15, ALOX15B | LMNA 3617/4885PKM 3290/4885ACHE 2721/4885 |
| US-20110085984-A1 | Drug Product and Process for Making | CYP2D6, CYP3A5, CYP2B6 | LMNA 2153/4885PKM 2458/4885ACHE 1656/4885 |
| US-20060052365-A1 | Protease inhibitors | CTSS, CTSE, CMA1 | LMNA 1372/4885PKM 3396/4885ACHE 856/4885 |
| US-20060073099-A1 | Treatment screening methods | HSD17B11, HSD3B2, HSD3B1 | LMNA 1231/4885PKM 4104/4885ACHE 1389/4885 |
| US-20170081431-A1 | METALLOCENE COMPLEX AND METHOD FOR PRODUCING OLEFIN POLYMER | PPOX, ALOX12, PORCN | LMNA 3871/4885PKM 1803/4885ACHE 3668/4885 |
| US-20070053832-A1 | Drug product and process for making | CYP2D6, CYP3A5, CYP2B6 | LMNA 2153/4885PKM 2458/4885ACHE 1656/4885 |
| US-20150266914-A1 | METALLOCENE COMPLEX AND OLEFIN POLYMERIZATION METHOD | POR, OPRM1, ALOX12 | LMNA 3913/4885PKM 1485/4885ACHE 3496/4885 |
| US-20070077201-A1 | Stem cell expansion and uses | NES, CD44, FGF2 | LMNA 1325/4885PKM 4694/4885ACHE 4757/4885 |
| US-20110137057-A1 | Unsaturated Steroid Compounds | SREBF1, SREBF2, NR1H3 | LMNA 731/4885PKM 3571/4885ACHE 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.